(NASDAQ: PLRX) Pliant Therapeutics's forecast annual revenue growth rate of 17.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Pliant Therapeutics's revenue in 2023 is $3,545,000.On average, 6 Wall Street analysts forecast PLRX's revenue for 2023 to be $106,974,181, with the lowest PLRX revenue forecast at $94,635,614, and the highest PLRX revenue forecast at $166,510,763. On average, 3 Wall Street analysts forecast PLRX's revenue for 2027 to be $7,236,809,333, with the lowest PLRX revenue forecast at $2,951,073,851, and the highest PLRX revenue forecast at $11,397,002,888.
In 2028, PLRX is forecast to generate $21,117,218,432 in revenue, with the lowest revenue forecast at $3,629,754,951 and the highest revenue forecast at $41,841,519,380.